Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep in 3rd line HR+/HER2 negative breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 16, 2024 10:13pm

72 Views

Post# 36226528

RE:RE:RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancer

Well that is most interesting as it has always been stated that we felt that 1st line patients would most likely do better as they had a stronger immune system compared to patients that had gone through previous chemo and were therefore had a more compromised immune system.
So note u are saying that 3rd line patients immune systems are as good as 1st line. Hmmm

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments